Metagenomi Therapeutics, Inc. (MGX)
NASDAQ: MGX · Real-Time Price · USD
1.600
+0.120 (8.11%)
At close: Mar 9, 2026, 4:00 PM EDT
1.610
+0.010 (0.62%)
After-hours: Mar 9, 2026, 7:40 PM EDT
Metagenomi Therapeutics Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| Cash & Equivalents | 41.72 | 27.39 | 140.6 | 184.44 | 39.3 |
| Short-Term Investments | 119.08 | 220.92 | 130.58 | 177.69 | 68.86 |
| Cash & Short-Term Investments | 160.8 | 248.31 | 271.18 | 362.13 | 108.15 |
| Cash Growth | -35.24% | -8.43% | -25.11% | 234.83% | - |
| Accounts Receivable | 0.31 | 1.26 | 2.45 | 1.27 | - |
| Other Receivables | 1.2 | 1.6 | 1 | 0.3 | 0.49 |
| Receivables | 1.51 | 2.86 | 3.45 | 1.57 | 0.49 |
| Prepaid Expenses | 3.23 | 6.8 | 3.64 | 3.19 | 0.27 |
| Total Current Assets | 165.54 | 257.96 | 278.27 | 366.9 | 108.92 |
| Property, Plant & Equipment | 47.38 | 57.66 | 65.15 | 33.26 | 21.89 |
| Long-Term Investments | 2.15 | 3.45 | 10.68 | 7.81 | 6.42 |
| Long-Term Deferred Charges | 0.6 | - | 5.1 | - | 0.14 |
| Other Long-Term Assets | 5.43 | 5.54 | 5.64 | 6.52 | 4.63 |
| Total Assets | 221.1 | 324.6 | 364.84 | 414.49 | 141.99 |
| Accounts Payable | 1.49 | 0.53 | 1.79 | 2.01 | 1.35 |
| Accrued Expenses | 6.72 | 8.35 | 11.03 | 7.89 | 3.15 |
| Current Portion of Leases | 6.03 | 5.59 | 3.43 | 1.52 | 0.69 |
| Current Income Taxes Payable | - | - | 3.27 | 1.54 | - |
| Current Unearned Revenue | 8.7 | 22.76 | 48.91 | 34.69 | 19.6 |
| Other Current Liabilities | 0 | 0.07 | 0.45 | 0.9 | 0.38 |
| Total Current Liabilities | 22.93 | 37.31 | 68.86 | 48.54 | 25.17 |
| Long-Term Debt | - | - | - | - | 30.28 |
| Long-Term Leases | 34.63 | 40.19 | 44.8 | 17.06 | 17.97 |
| Long-Term Unearned Revenue | 2.99 | 10.24 | 30.93 | 76.19 | 24.63 |
| Other Long-Term Liabilities | 1.95 | 2.01 | 5.08 | 1.03 | - |
| Total Liabilities | 62.51 | 89.74 | 149.67 | 142.81 | 98.04 |
| Common Stock | 0 | 0 | - | 0.03 | 0.03 |
| Additional Paid-In Capital | 469.2 | 457.15 | 9.46 | - | - |
| Retained Earnings | -310.87 | -223 | -144.94 | -76.69 | -33.1 |
| Comprehensive Income & Other | 0.26 | 0.71 | -0.1 | 2.24 | 0.53 |
| Total Common Equity | 158.6 | 234.86 | -135.58 | -74.43 | -32.54 |
| Shareholders' Equity | 158.6 | 234.86 | 215.17 | 271.68 | 43.95 |
| Total Liabilities & Equity | 221.1 | 324.6 | 364.84 | 414.49 | 141.99 |
| Total Debt | 40.66 | 45.78 | 48.23 | 18.57 | 48.93 |
| Net Cash (Debt) | 120.14 | 202.53 | 222.95 | 343.56 | 59.23 |
| Net Cash Growth | -40.68% | -9.16% | -35.10% | 480.08% | - |
| Net Cash Per Share | 3.23 | 6.13 | 65.49 | 101.06 | 10.41 |
| Filing Date Shares Outstanding | 37.62 | 37.38 | 37.47 | 5.95 | 5.69 |
| Total Common Shares Outstanding | 37.62 | 37.42 | 5.95 | 5.95 | 5.69 |
| Working Capital | 142.61 | 220.65 | 209.41 | 318.36 | 83.74 |
| Book Value Per Share | 4.22 | 6.28 | -22.80 | -12.51 | -5.72 |
| Tangible Book Value | 158.6 | 234.86 | -135.58 | -74.43 | -32.54 |
| Tangible Book Value Per Share | 4.22 | 6.28 | -22.80 | -12.51 | -5.72 |
| Machinery | 23.86 | 24.49 | 21.8 | 13.84 | 3.24 |
| Construction In Progress | - | 0.14 | 2.35 | 1.4 | 0.89 |
| Leasehold Improvements | 4.39 | 4.38 | 3.83 | 3.53 | 0.29 |
Source: S&P Capital IQ. Standard template. Financial Sources.